Daus W, Kaps D, Völcker H E
Universitätsaugenklinik Heidelberg.
Klin Monbl Augenheilkd. 1990 Nov;197(5):426-31. doi: 10.1055/s-2008-1046305.
A 46 year old AIDS-patient, who had developed CMV-retinitis was treated with the virostatic drug dihydroxypropoxymethylguanine (DHPG, Ganciclovir) over a period of 16 months until he died due to a pneumonia. After the DHPG-treatment was initiated the retinitis improved markedly, however there still was a very slow progression of the disease in the following time. The central retina of both eyes was not affected until death. Postmortal immunohistochemically CMV-antigen-staining was positive according to the former clinically active retinitis. At the eyes of the retinal necrosis calcified deposits were identified by Kossa-staining; these areas had clinically appeared as yellowish briddle deposits. The clinical course and the immunohistochemical proof of active CMV-virus-particles suggest that DHPG was able to suppress the progression of a CMV-retinitis and to preserve a good visual acuity until death; however a true cure of the CMV-infection could not be achieved.
一名46岁的艾滋病患者，已发展为巨细胞病毒性视网膜炎，接受了16个月的抗病毒药物二羟丙氧甲基鸟嘌呤（DHPG，更昔洛韦）治疗，直至因肺炎死亡。开始使用DHPG治疗后，视网膜炎明显改善，但在随后的时间里疾病仍有非常缓慢的进展。直到死亡，双眼的中央视网膜均未受影响。死后免疫组化CMV抗原染色根据先前临床活跃的视网膜炎呈阳性。在视网膜坏死区域，通过科萨染色鉴定出钙化沉积物；这些区域在临床上表现为淡黄色斑点状沉积物。临床病程及活性CMV病毒颗粒的免疫组化证据表明，DHPG能够抑制巨细胞病毒性视网膜炎的进展，并在死亡前保持良好的视力；然而，巨细胞病毒感染并未真正治愈。
